Advances Changing the Treatment Landscape of AML
Kamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia. After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.
Kamal Menghrajani, MD, a hematologist/oncologist at Memorial Sloan Kettering Cancer Center, discusses the latest advancement in the research of acute myeloid leukemia (AML). After treating this disease the same way with traditional chemotherapy for over 40 years, researchers have finally come to an understanding of what is happening in the AML cells, leading to a more precise treatment of these patients.
While there has been little to no advance in the treatment landscape for several decades, understanding what happens in AML cells as they develop has helped advance the field in a number of ways, Menghrajani says. The first major advance includes CPX-351 (Vyxeos), a combination of 2 different chemotherapies. By combining these traditional chemotherapies, the new formula can target AML better than either of the 2 agents could alone.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
